The DP receptor, allergic inflammation and asthma

IF 3.2 Prostaglandins, leukotrienes, and essential fatty acids Pub Date : 2003-08-01 DOI:10.1016/S0952-3278(03)00080-2

Kenji Kabashima, Shuh Narumiya

{"title":"The DP receptor, allergic inflammation and asthma","authors":"Kenji Kabashima, Shuh Narumiya","doi":"10.1016/S0952-3278(03)00080-2","DOIUrl":null,"url":null,"abstract":"<div><div>Prostaglandin (PG) D2 is the major cyclooxygenase metabolite of arachidonic acid produced by mast cells in response to allergen in diseases, such as asthma, atopic dermatitis, allergic rhinitis and allergic conjunctivitis. However, whether PGD2 regulates allergic process per se, and, if so, whether it facilitates or down-regulates the disease process has remained unknown. PGD2 exerts its actions by binding to two types of specific cell surface receptor. One is DP (the PGD receptor) and the other is chemoattractant receptor-homologous molecule expressed on Th2. Between the two, the DP receptor has been better characterized since its cDNA cloning in 1994, and novel class of DP antagonists have been and are being developed. Furthermore, mice deficient in DP were generated and have been subjected to several models of allergic diseases to reveal the role of PGD2 in allergy. In this article, we summarize these findings and provide an overview of the current status of the DP receptor research to discuss the therapeutic potential of modulating the PGD2-DP pathway in allergic diseases.</div></div>","PeriodicalId":94179,"journal":{"name":"Prostaglandins, leukotrienes, and essential fatty acids","volume":"69 2","pages":"Pages 187-194"},"PeriodicalIF":3.2000,"publicationDate":"2003-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins, leukotrienes, and essential fatty acids","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952327803000802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Prostaglandin (PG) D₂ is the major cyclooxygenase metabolite of arachidonic acid produced by mast cells in response to allergen in diseases, such as asthma, atopic dermatitis, allergic rhinitis and allergic conjunctivitis. However, whether PGD₂ regulates allergic process per se, and, if so, whether it facilitates or down-regulates the disease process has remained unknown. PGD₂ exerts its actions by binding to two types of specific cell surface receptor. One is DP (the PGD receptor) and the other is chemoattractant receptor-homologous molecule expressed on Th2. Between the two, the DP receptor has been better characterized since its cDNA cloning in 1994, and novel class of DP antagonists have been and are being developed. Furthermore, mice deficient in DP were generated and have been subjected to several models of allergic diseases to reveal the role of PGD₂ in allergy. In this article, we summarize these findings and provide an overview of the current status of the DP receptor research to discuss the therapeutic potential of modulating the PGD₂-DP pathway in allergic diseases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

DP受体，过敏性炎症和哮喘

前列腺素（PG） D2是花生四烯酸的主要环加氧酶代谢物，在哮喘、特应性皮炎、变应性鼻炎和过敏性结膜炎等疾病中，肥大细胞对过敏原产生反应。然而，PGD2本身是否调节过敏过程，如果是，它是促进还是下调疾病过程仍然未知。PGD2通过结合两种特定的细胞表面受体发挥作用。一种是PGD受体DP，另一种是Th2上表达的趋化剂受体同源分子。其中，DP受体自1994年cDNA克隆以来已被较好地表征，并且一类新的DP拮抗剂已经和正在开发中。此外，产生了DP缺乏的小鼠，并进行了几种变应性疾病模型，以揭示PGD2在过敏中的作用。在本文中，我们总结了这些发现，并概述了DP受体的研究现状，以讨论调节PGD2-DP通路在变应性疾病中的治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊